Trial Updates Archives

First-line maintenance with olaparib monotherapy and in combination bevacizumab increases survival in advanced ovarian cancer

Over 75% of patients with ovarian cancer are diagnosed at an advanced stage, as early-stage disease is usually asymptomatic.1,2 The…

TROPiCS-02: Overall survival benefit of sacituzumab govitecan in HR+/HER2- metastatic breast cancer

Antibody-drug conjugates (ADCs) are an emerging class of anticancer drugs consisting of a monoclonal antibody linked to a cytotoxic chemotherapy…

New research elucidates how air pollution causes lung cancer in never-smokers

Research presented at the European Society of Medical Oncology (ESMO) Congress 2022 has uncovered a non-mutagenic mechanism by which air…

EV-103 Cohort K: Promising data for first-line combination therapy of enfortumab vedotin plus pembrolizumab for patients with urothelial carcinoma

EV-103 (NCT03288545) is a multicohort study investigating the use of the antibody-drug conjugate, enfortumab vedotin, alone or in combination with…

Top picks from WCLC 2022: NADIM II, IMpower010, CALGB 140503, YESS

VJOncology are thrilled to present our top picks from the the IASLC 2022 World Conference on Lung Cancer (WCLC) congress!

MOUNTAINEER: Tucatinib plus trastuzumab demonstrates good efficacy for the treatment of HER2-positive metastatic colorectal cancer

In the U.S., colorectal cancer (CRC) is the third leading cause of cancer-related deaths and is expected to lead to…

Highlights from ASCO 2022

VJOncology are excited to present our top picks from the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting!

177Lu-PSMA-617 approved for use in patients with PSMA+ mCRPC

As of the 23rd March 2022, the U.S. Food and Drug Administration (FDA) has approved 177Lu-PSMA-617 (a.k.a. Lu 177 Vipivotide…

Top 5 picks from ASCO GU 2022

Catch the latest updates in GU with VJOncology from the American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2022!

Highlights from ASCO GI 2022

VJOncology brings you highlights in GI cancer from this year’s virtual American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium!

Top picks from SABCS 2021

The San Antonio Breast Cancer Symposium (SABCS) took place on the 7-10 December 2021, both virtually and in-person. We heard…

FDA grants priority review for fixed-dose relatlimab plus nivolumab in melanoma based on RELATIVITY-047

The U.S Food and Drug Administration (FDA) has granted priority review for the fixed-dose combination of relatlimab, a LAG-3 targeting…

Highlights from ESMO 2021

Check out our top picks from ESMO 2021!

FDA approves mobocertinib for NSCLC with EGFR exon 20 insertion mutations

The U.S. Food and Drug Administration (FDA) has granted accelerated approval of mobocertinib for patients with metastatic non-small cell lung…

Top 5 in lung from ASCO 2021

Highlights from ASCO 2021 in lung cancer! Learn more about the major clinical trials reported at this year’s meeting.

Key updates from EAU 2021

VJOncology presents highlights from this year’sEuropean Association of Urology (EAU) Virtual Meeting 2021!

features: Trial Updates